Key Drivers and Opportunities in the Denosumab Market: Insights into Trends and Growth
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Long-Term Growth Rate is Expected for the Denosumab Market Between 2025 and 2034?
There has been a swift expansion in the denosumab market size over the past few years. It is predicted that it will surge from $3.27 billion in 2024 to $3.7 billion in 2025, registering a compound annual growth rate (CAGR) of 13.1%. The upward trend during the historic period can be tied to factors such as advancements in clinical trials and research, FDA approvals and regulatory checkpoints, heightened awareness regarding bone health, along with strategic collaborations and marketing drives.
In the coming years, the market size for denosumab is predicted to expand rapidly. By 2029, it is forecasted to reach a worth of $5.59 billion with a compound annual growth rate (CAGR) of 10.9%. The expected growth within the forecast period can be tied to the increasing occurrences of bone metastases, progress in cancer treatments, the commonness of osteoporosis, and the augmented understanding of osteoporosis, together with regulatory green lights for new uses. Key trends within this period include strategic cooperation and partnerships, integration into digital health solutions, the growth of new uses and clinical applications, and advancements within biosimilar development.
Which Drivers Are Expected to Have the Greatest Impact on the denosumab Market’s Growth?
The growth of the denosumab market is anticipated to be boosted by the rising incidence of osteoporosis. Osteoporosis is a health condition which weakens the bones, leading to decreased bone density and increased fracture risk. Denosumab is employed in osteoporosis treatment by inhibiting bone resorption via the targeted RANK ligand. As indicated by data from the National Center for Biotechnology Information, a US governmental agency, the Canadian Longitudinal Study on Aging in September 2023 showed the prevalence of physician-diagnosed osteoporosis to be 12.7% and DXA-proven osteoporosis at 5.9% for female community-dwelling elderly. Furthermore, a cross-sectional study executed by Buttros et al revealed the incidence of osteoporosis in postmenopausal women aged between 40 and 75 to be 24.6%, diagnosed using bone mineral density (BMD) measurements. This surge in osteoporosis incidence is therefore propelling the denosumab market expansion.
Get Your Free Sample of the Global Denosumab Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp
What Are the Key Firms That Are Driving Transformation in the Denosumab Market?
Major companies operating in the denosumab market report are:
• Johnson & Johnson_x000D_
• F. Hoffmann-La Roche Ltd._x000D_
• Novartis International AG_x000D_
• Sanofi SA_x000D_
• GlaxoSmithKline plc_x000D_
What Current Trends in the Denosumab Market Should Industry Players Pay Attention To?
Leading players in the denosumab market are striving to maintain their competitive stance by rolling out innovative solutions, including premier treatments for osteoporosis. The term “first-line treatment for osteoporosis” refers to the initial treatment method endorsed by medical practitioners for individuals diagnosed with the bone condition. As an example, in November 2022, China’s Boan Biotech secured approval from the country’s National Medical Products Administration (NMPA) for its denosumab biosimilar product, Boyoubei, becoming the first company in China to produce a denosumab injection. The company is also preparing it for markets beyond China, including Europe and the United States, with an aim to globally market it. Various treatment guidelines have suggested the drug as a superior treatment for osteoporosis. The drug potentially promises to significantly reduce the risk of hip, non-vertebral, and vertebral fractures among this group of patients. Moreover, Boyoubei is the world’s first biosimilar to Prolia (the original creator of denosumab) granted approval for global distribution.
Get Instant Access to the Global Denosumab Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report
Which Growth-Oriented Segments of the Denosumab Market Are Leading the Industry’s Development?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
What Regions Are Driving Expansion in the Denosumab Market?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Parameters Define the Denosumab Market’s Scope?
Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture.
Browse Through More Similar Reports By The Business Research Company:
Antifungals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Antiobesity Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Anemia And Other Blood Disorder Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
